Peer Exchange

Overview of Cardiovascular Risks

Prevalence of CVD Associated With Hypercholesterolemia

CVD Risk Reduction and Prevention

CVD: REDUCE-IT Trial

CVD: EVAPORATE Trial and COVID-19 Pilot Study

Add-On Therapy With Statins and PCSK9 Inhibitors in CVD

Adverse Effects of PCSK9 Inhibitors in CVD

CVD Real-World Case Scenario 1

CVD Real-World Case Scenario 2

CVD Real-World Case Scenario 3

Treatment of CVD: Bempedoic Acid Monotherapy + Ezetimibe

Emerging Therapies for the Treatment of CVD

Closing Thoughts for the Management of CVD

Psoriatic Arthritis Patient Case Overview and Therapeutic Goals

Atopic Dermatitis: Age of Onset and Prevalence

Impact of Atopic Dermatitis: Pediatrics Versus Adults

Presentation and Severity of Atopic Dermatitis

Seeking Care for Atopic Dermatitis

Nonpharmacological Approach to Managing Atopic Dermatitis

Pediatric AD: State-of-the-Art Treatment

Moderate to Severe Disease: Systemic Therapy

Monoclonal Antibody Therapy for Pediatrics With AD

Monoclonal Antibody Prior Authorization

Topical Therapy Approach for Pediatric Atopic Dermatitis

First-Line Biologics for Pediatric AD and Psoriasis

The Shifting Treatment Paradigm in AD Management

Atopic Dermatitis Pathophysiology

Pediatric AD: Differential Diagnosis and Tools

Monoclonal Antibody FDA Approval for Pediatric Population

Monoclonal Antibody Toxicity Profile and Patient Impact

Developing Treatments for Pediatric Atopic Dermatitis

Pathogenesis of Inflammatory Bowel Disease

Identifying Progressive, Relapsing IBD

Inflammatory Bowel Disease Risk Stratification

IBD Prognostication and Management

Diagnosing Inflammatory Bowel Disease

Goals of Therapy for Inflammatory Bowel Disease

T2T Approach for Inflammatory Bowel Disease

Treating a Low-Risk Inflammatory Bowel Disease

Treating Moderate/High-Risk IBD

Surgery for an Inflammatory Bowel Disease

Biologic Therapies for Inflammatory Bowel Disease

Therapeutic Outcomes for Patients With IBD

Implications of UNIFI in Ulcerative Colitis

IBD: Clinical Trial End Points and Treatment Guidance

Implications of the GEMINI Trial in IBD

Inflammatory Bowel Disease Treatment Selection

Switching Between Biologics for IBD

Optimizing Outcomes When Switching Biologics in IBD

Novel Therapies in the IBD Pipeline

Treatment Challenges in IBD

Role of Specialty Pharmacy in IBD Management

Managing Inflammatory Bowel Diseases in the Community

Challenges in Treating Schizophrenia

Counseling Patients With Schizophrenia on Relapse

Schizophrenia Relapses and Patient Well-Being

Treatment Nonadherence and Schizophrenia Relapses

Socioeconomic Burden of Treatment Adherence in Schizophrenia

Psychosocial Interventions for Schizophrenia

Challenges With Oral Antipsychotics for Schizophrenia

Long-Acting Injectable Antipsychotics for Schizophrenia

Barriers to Prescribing LAIs for Schizophrenia

Misperceptions and Underutilization of LAIs for Schizophrenia

NCBH Guidelines and LAI Therapy for Schizophrenia

Advantages of LAI Antipsychotics for Schizophrenia

Dosing LAI Antipsychotics for Schizophrenia

Early Initiation of LAI Therapy for Schizophrenia

Current LAI Options for Schizophrenia

Second-Generation LAIs for Schizophrenia

LAI Treatment Selection and Patient Factors

Patient-Physician Collaboration and Schizophrenia Outcomes

Schizophrenia Treatment: Overcoming Obstacles

Schizophrenia Treatment and Outlook

Clinical Subtypes of ADHD

Factors That Predispose for ADHD

ADHD: Patient QOL and Misconceptions

What Prompts Patients to Seek an Evaluation for ADHD

Accurately Diagnosing ADHD

Challenges With Diagnosing ADHD

Non-Pharmacological Strategies for ADHD

Non-Stimulant Therapy for ADHD

Short- and Intermediate-Acting Stimulants for ADHD

Long-Acting Stimulants for ADHD

Prodrug Therapy for ADHD

Treatments for ADHD: Efficacy and Safety Data

Substance Abuse and ADHD

Adult ADHD Treatment Recommendations

Switching Medication for ADHD

Multimodal Treatment of ADHD

Novel Nonstimulant Therapy for ADHD

Exciting Therapies Under Investigation for ADHD

Treating ADHD: Current Unmet Needs

Managing ADHD During COVID-19

Evolution of Therapy and Destigmatizing ADHD